Last reviewed · How we verify
HL231 Solution for Inhalation
HL231 is an inhaled formulation designed to deliver therapeutic agents directly to the respiratory tract for local and/or systemic effects.
At a glance
| Generic name | HL231 Solution for Inhalation |
|---|---|
| Sponsor | Haisco Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a solution for inhalation, HL231 enables direct pulmonary delivery of its active pharmaceutical ingredient(s), potentially improving bioavailability and reducing systemic exposure compared to oral or parenteral routes. The specific mechanism depends on the active ingredient, which is not publicly disclosed in available sources. Inhalation formulations are typically used for respiratory conditions or to achieve rapid systemic absorption through the large surface area of the lungs.
Approved indications
Common side effects
Key clinical trials
- A Trial to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients with COPD (PHASE2)
- A Study to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients with COPD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HL231 Solution for Inhalation CI brief — competitive landscape report
- HL231 Solution for Inhalation updates RSS · CI watch RSS
- Haisco Pharmaceutical Group Co., Ltd. portfolio CI